At a glance
Lab supply demand, Q3 2026
Exhibit 1Lab and life science suppliers, organic growth
Latest quarter
The category on a page
Exhibit 2Where lab supplies sit
Profit impact against supply risk, R&D subcategories
Exhibit 4Thermo Fisher by segment
Q3 2026 organic growth
Typical savings vs unmanaged buying
Distribution tender and core list
Value levers
In order of value.
Run a primary distributor tender now while they fight for share.
Fixed prices on the top 300-500 items.
Steer scientists to contracted items in the buying system.
Approve equivalents for plastics and common reagents.
Multi-year supply for resins, filters and bags.
Agree how tariffs and FX are passed on.
How to buy it
KPIs to track
For the monthly review
Where most buyers are, and what good looks like
| Most buyers today | Best practice | ||
|---|---|---|---|
| Channel | Many small suppliers | → | Primary distributor |
| Pricing | List minus discount | → | Fixed core list |
| Buying | Free text orders | → | Punch-out catalogues |
| Spec | Brand only | → | Approved equivalents |
| Data | None | → | Line-item spend analytics |
What AI changes
More in the AI disruption tab.
Full written analysis
Written live for Lab supplies and your region, grounded on the figures above. Public data only.
Written live for this category and region when the page opens in a browser.
Negotiation playbook
Negotiation playbook
Distributors are competing on price while demand recovers. Your leverage is volume consolidation and the ability to switch catalogue.
Pick the right commercial model
| Fixed core list + discountUsual best | Fixed on top items; % off list for tail. |
| Cost-plus distribution | Transparent margin over manufacturer cost. |
| Discount off list | Simple; exposed to list rises. |
| Vendor-managed inventory | Supplier stocks your stores. |
Questions to ask suppliers
- List increases
Will you cap annual list price increases at an agreed level for the contract term?
Good answer: capped. - Core list
Will you fix prices on our top 500 items for two years?
Good answer: fixed prices. - Substitutes
Which equivalent products can you offer for our top items, and at what saving?
Good answer: cheaper equivalents. - Service
What next-day delivery rate will you guarantee, with credits if missed?
Good answer: delivery levels. - Rebates
What rebate applies if we move more of our spend to you?
Good answer: volume tiers. - Tariffs
How will you show the actual tariff cost before passing it on?
Good answer: evidence before change.
Your leverage
- Consolidated volume
- Distributor competition
- Equivalent products
- Multi-year term
Watch out for
- List increases above inflation
- Off-contract buying
- Tariff surcharges without evidence
- Minimum order fees
AI disruption
Tailwinds for buyers
- Spend analytics clean item data.
- AI recommends equivalents.
- Automated reordering.
- Lab automation lowers error rates.
- Demand forecasting reduces waste.
- Chatbots for supplier queries.
Headwinds for buyers
- Automation platforms lock in consumables.
- Proprietary reagents for AI labs.
- Data from lab instruments held by vendors.
- Higher capital costs.
- Validation of new methods.
- Cyber risk in connected instruments.
How to capture it
Ask for open consumables and data on automated platforms before you buy them.
Who is changing the market
- Combines AI, robotics and its own instruments
- Shifts buying toward integrated platforms
- Opened its first such centre in South Korea
- Bundles analytics, automation and AI for labs
- Revival programme is improving service and growth
- Competing on price to win distribution contracts
Risk radar
Risk radar
Exposure by dimension, 0-100, Global
Risk heat map
Impact against likelihood; numbers match the register below
- Tariffs on consumables
- List price creep
- Bioprocess consumable shortages
- Platform lock-in
Risk register
US Section 232 probe into medical consumables.
Annual list increases on long tails.
Bioprocessing orders up mid-teens.
Automated labs tie you to one brand's consumables.
Market pulse
What the biggest suppliers are reporting
From their latest results and investor material.
Q3 2026. Lab products and biopharma services +15% (10% organic); Life Sciences Solutions +1% organic; China up low double digits; FY organic guide 4%.
Q3 2026. First organic growth in years; VWR distribution +5.8% but its margin fell to 9.7%; FY organic guide raised to +0.75-1.25%.
Q3 2026. Bioprocessing orders up mid-teens; Life Sciences core +4.5%; China high single digits, developed markets flat.
9M 2026. Sales EUR 2.74bn; Stedim paid EUR 28m tariff compensation to customers; full-year guide confirmed.
Q2 2026 (latest). Life Science EUR 2.4bn; Process Solutions the main driver; agreed to buy Bio-Techne.
Latest developments
Dated, newest first. Checked 16 Nov 2026.
Organic +5.2%; VWR margin 9.7%.
So what: Distributors are buying share; tender now.
Avantor (SEC) →Lab products +10% organic.
So what: Demand recovery will firm prices in 2027.
Thermo Fisher Q3 2026 results and call →Core +5.5%; AI autonomous lab launched.
So what: Secure resin and filter supply for 2027.
Danaher Q3 2026 results and call →Stedim paid EUR 28m tariff compensation.
So what: Ask suppliers what tariff costs they absorb.
Sartorius →Life Science organic +8%.
So what: Consolidation; check overlap in your reagents.
Analytica World →What this means for your next negotiation
- Distributors are competing on price; run your tender before 2027 list increases.
- Fix prices on core items and cap list increases.
- Lock bioprocess consumables as orders rise.
Signals to watch next quarter
Usually announced in January.
Section 232 probe.
Product range changes.
Sources
- Thermo Fisher Q3 2026 results and call · 21 Oct 2026
- Avantor Q3 2026 (SEC) · 28 Oct 2026
- Danaher Q3 2026 results and call · 21 Oct 2026
- Sartorius 9M 2026 · 22 Oct 2026
- Merck KGaA Q2 2026 · 10 Aug 2026
Figures checked 16 Nov 2026. Tags: Official = published by the source; Derived = calculated from published figures; Judgement = The Procurement Lens view.